Pandemic of coronavirus disease (COVID-19) is still pressing the healthcare systems
worldwide. Thus far, the lack of available COVID-19-targeted treatments has led scientists to …

At the end of 2019, the whole world was witnessing the birth of a new member of the Severe
Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) family in Wuhan city, China …

Pharmacologists, pharmacists, and other drug experts have been at the forefront during the
COVID-19 outbreak. Pharmacological expertise was required in various areas such as the …

Abstract Coronavirus disease 2019 (COVID-19) is a disease caused by severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) and can be aggravated by comorbid …

COVID-19 is announced as a global pandemic in 2020. Its mortality and morbidity rate are
rapidly increasing, with limited medications. The emergent outbreak of COVID-19 prompted …

Patients with COVID‐19 are sometimes already being treated for one or more other chronic
conditions, especially if they are elderly. Introducing a treatment against COVID‐19, either …

As global health services respond to the coronavirus pandemic, many prescribers are
turning to experimental drugs. This review aims to assess the risk of drug–drug interactions …

Elderly patients are at high risk of corona virus disease 2019 (COVID-2019) infection and
severe COVID-19 patients are treated in intensive care units (ICU). Drug-drug interaction …

Objectives Coronavirus disease 2019 (COVID-19) is an emerging viral infection without any
approved treatment. Investigational therapies for COVID-19 may cause clinically important …

Drug-drug interactions (DDI) potentially occurring between medications used in the course
of COVID-19 infection and medications prescribed for the management of underlying …